AT-rich interactive domain-containing protein 3A (ARID3A)

ARID3A (AT-rich interactive domain-containing protein 3A) is a member of the ARID family of DNA-binding proteins. It was originally discovered as a transcription factor that increases immunoglobulin heavy chain transcription in activated B cells and is essential for B cell differentiation and maturation[3]. ARID3A contains a conserved ARID DNA-binding domain and functions as a chromatin remodeler, forming complexes with other ARID proteins (e.g., ARID3B)[1]. It is capable of distorting DNA structure and interacting with spatially distant regulatory elements, thus influencing enhancer-promoter interactions. ARID3A can regulate cell cycle progression, rescue RAS-induced cellular senescence, interact with key cell cycle and tumor suppressor proteins (E2F1, retinoblastoma, p53), and modulate stem cell genes (Oct4, Sox2, Nanog)[1][3][5]. Dysregulation of ARID3A is linked to cancer, altered hematopoiesis, and autoimmunity. It is mainly localized in the nucleus but can shuttle between the nucleus and cytoplasm depending on the cell cycle phase. No approved drugs directly target ARID3A as of the current knowledge[1][3][5].

Other names

BrightB-cell regulator of IgH transcriptionDead ringer-like protein 1DRIL1DRIL3DRXE2F-binding protein 1 (E2FBP1)ARID domain-containing protein 3A

No direct drugs targeting ARID3A reported in search results. Hypothetically, drugs could modulate its function by affecting transcriptional regulatory complexes or post-translational modification, but specific mechanisms have not been described[1][3].